Clover Health Investments, Corp. (NASDAQ: CLOV) is a Healthcare company (Medical - Healthcare Plans) with a market capitalization of $2.5B. The Maz Rating grades it against the other companies in its sector.
Clover Health Investments, Corp.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $4.73, Clover Health Investments, Corp. trades at 276.5x trailing earnings, 0.9x sales and 6.4x book value, with an EV/EBITDA of 152.9. Over the last twelve months it generated about $2.8B of revenue and $9M of net income. It runs a gross margin of 18.9%, an operating margin of 0.5% and a net margin of 0.5%. It shows return on equity of 3.5%, return on invested capital of 3.1% and a free cash flow yield of 5.3%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 1.55. Over the past 52 weeks the share price ranged from $1.58 to $5.59, with a beta of 2.48.
Clover Health Investments, Corp. does not currently pay a dividend.
9 Wall Street analyst ratings cover the stock: 1 Buy, 5 Hold and 3 Sell, for a Hold consensus. This is the sell side's view, separate from the Maz Rating.
Clover Health Investments, Corp. is a U.S.-based firm specializing in Medicare Advantage insurance. The company leverages its proprietary software platform, the Clover Assistant, to provide both Preferred Provider Organization (PPO) and Health Maintenance Organization (HMO) health plans for individuals eligible for Medicare. In addition to its insurance operations, Clover Health also engages in non-insurance-related business ventures. The company was established in 2014 and its main office is located in Franklin, Tennessee.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, Clover Health Investments, Corp. (CLOV) passes 4 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global, Dow Jones and MSCI, and fails FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 18.5% / 30% · Interest income / Revenue 0.00% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 11.4% / 33% · Receivables / Mkt Cap (36m) 7.12% / 49% · Interest income / Revenue 0.00% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 11.4% / 33.33% · Receivables / Mkt Cap (24m) 7.12% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 0.00% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 27.5% / 33.33% · Receivables / Avg Assets (4Q) 27.0% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 36.2% / 33.33% · (Cash+Recv) / Total Assets 58.7% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
It depends on the standard you follow. As of September 2026, Clover Health Investments, Corp. (CLOV) passes 4 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global, Dow Jones and MSCI, and fails FTSE.
Yes. Clover Health Investments, Corp. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
Clover Health Investments, Corp. reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.